• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Wooster Richard

    6/10/24 4:15:08 PM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IKNA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Wooster Richard

    (Last) (First) (Middle)
    C/O IKENA ONCOLOGY, INC.
    645 SUMMER STREET, SUITE 101

    (Street)
    BOSTON MA 02210

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Ikena Oncology, Inc. [ IKNA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/07/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $1.75 06/07/2024 A 17,520 (1) 06/06/2034 Common Stock 17,520 $0.00 17,520 D
    Explanation of Responses:
    1. This option shall vest in full upon the earlier of (i) June 7, 2025 or (ii) the date of the next annual meeting; provided, however, that all vesting shall cease if the director resigns from the Board or otherwise ceases to serve as a director.
    /s/ Mark Manfredi, as Attorney-in-Fact for Richard Wooster 06/10/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $IKNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IKNA

    DatePrice TargetRatingAnalyst
    5/29/2024$8.00 → $2.00Outperform → Neutral
    Wedbush
    9/22/2023$11.00Outperform
    Wedbush
    5/4/2023$18.00Buy
    H.C. Wainwright
    12/23/2021$25.00Buy
    HC Wainwright & Co.
    8/13/2021$30.00 → $27.00Outperform
    Credit Suisse
    More analyst ratings

    $IKNA
    SEC Filings

    See more
    • Amendment: SEC Form S-4/A filed by Ikena Oncology Inc.

      S-4/A - Ikena Oncology, Inc. (0001835579) (Filer)

      5/30/25 4:47:59 PM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form S-4/A filed by Ikena Oncology Inc.

      S-4/A - Ikena Oncology, Inc. (0001835579) (Filer)

      5/20/25 5:04:24 PM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Ikena Oncology Inc.

      10-Q - Ikena Oncology, Inc. (0001835579) (Filer)

      5/8/25 8:00:17 AM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IKNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Wooster Richard

      4 - Ikena Oncology, Inc. (0001835579) (Issuer)

      6/10/24 4:15:08 PM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Dukes Iain D.

      4 - Ikena Oncology, Inc. (0001835579) (Issuer)

      6/10/24 4:15:06 PM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Formela Jean Francois

      4 - Ikena Oncology, Inc. (0001835579) (Issuer)

      6/10/24 4:15:09 PM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IKNA
    Financials

    Live finance-specific insights

    See more

    $IKNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction

      Ikena receives approximately $43 million in net cash at closing New capital will further accelerate and expand development of Ikena's targeted oncology pipeline BOSTON and SOUTH SAN FRANCISCO, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena"))), a targeted oncology company forging new territory in patient-directed cancer treatment, and Pionyr Immunotherapeutics, Inc. (Pionyr), a privately-held, clinical-stage biotechnology company, today announced the closing of Ikena's acquisition of Pionyr in an all-stock transaction. Ikena acquired all of Pionyr's assets, including approximately $43 million in net cash, in exchange for shares of IKNA stock, in a com

      8/7/23 7:00:00 AM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Ikena Oncology Inc.

      SC 13G - Ikena Oncology, Inc. (0001835579) (Subject)

      11/14/24 5:05:17 PM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ikena Oncology Inc.

      SC 13G/A - Ikena Oncology, Inc. (0001835579) (Subject)

      11/13/24 4:05:14 PM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Ikena Oncology Inc. (Amendment)

      SC 13G/A - Ikena Oncology, Inc. (0001835579) (Subject)

      3/11/24 8:19:04 AM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IKNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Traws Pharma Announces Management Updates

      Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the retirement of Werner Cautreels, PhD, Chief Executive Officer (CEO), effective on or about close of business on March 31, 2025 after the Company files its Annual Report on Form 10-K with the Securities and Exchange Commission. Iain D. Dukes, D Phil, will assum

      3/28/25 4:30:00 PM ET
      $IKNA
      $IOVA
      $TRAW
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement

      Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function The transaction is expected to result in approximately $175 million to support further development of IMG-007, including $75 million from an oversubscribed Private Placement that will close immediately following the merger The Financing includes both new investors such as Deep Track Capital, Foresite Capital, RTW Investments, and existing Ikena investors such as BVF Partners L.P., Blue Owl Healthcare Opportunities, Omega Funds, and OrbiMed The transaction is expected to close in mid-2025

      12/23/24 8:30:00 AM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ikena Oncology Reports Third Quarter 2024 Financial Results

      BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena, " "Company")) today announced financial results for the third quarter ended September 30, 2024, and provided an update regarding its ongoing activities. Pipeline and Corporate Updates Dose escalation in the Phase 1 study of IK-595 in patients with RAS and RAF mutant cancers continues, with multiple cohorts having cleared their safety evaluation period Promising early pharmacokinetics (PK) and pharmacodynamics (PD) activity has been observed, with dose dependent exposure and target modulation measured in the blood The Company continues to evaluate a range of potential strategic options to maximize shareho

      11/7/24 8:30:00 AM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IKNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ikena Oncology downgraded by Wedbush with a new price target

      Wedbush downgraded Ikena Oncology from Outperform to Neutral and set a new price target of $2.00 from $8.00 previously

      5/29/24 7:45:06 AM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wedbush initiated coverage on Ikena Oncology with a new price target

      Wedbush initiated coverage of Ikena Oncology with a rating of Outperform and set a new price target of $11.00

      9/22/23 7:17:31 AM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright resumed coverage on Ikena Oncology with a new price target

      H.C. Wainwright resumed coverage of Ikena Oncology with a rating of Buy and set a new price target of $18.00

      5/4/23 8:00:07 AM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IKNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Traws Pharma Announces Management Updates

      Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the retirement of Werner Cautreels, PhD, Chief Executive Officer (CEO), effective on or about close of business on March 31, 2025 after the Company files its Annual Report on Form 10-K with the Securities and Exchange Commission. Iain D. Dukes, D Phil, will assum

      3/28/25 4:30:00 PM ET
      $IKNA
      $IOVA
      $TRAW
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Ikena Oncology Reports Second Quarter 2024 Financial Results

      BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena, " "Company"))) today announced financial results for the second quarter ended June 30, 2024, and provided an update regarding its ongoing activities. Pipeline Updates Dose escalation in the Phase 1 study of IK-595 in patients with RAS and RAF mutant cancers continues, with multiple cohorts having cleared their safety evaluation period Promising early pharmacokinetics (PK) and pharmacodynamics (PD) activity has been observed, with dose dependent exposure and target modulation measured in the blood In May 2024, the Company announced the discontinuation of the IK-930 clinical program Corporate Updates In

      8/8/24 4:15:00 PM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update

      Strong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program continues dose escalation in patients with RAS and RAF mutant cancers BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena, " "Company"))), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the first quarter ended March 31, 2024. The Company also provided an update regarding its organization and pipeline. "We continue to execute thoughtfully and diligently on our clinical programs," said Mark Manfredi, Ph.D., Chief Executive

      5/13/24 4:45:00 PM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care